Subject expert committee (SEC) will discuss the Serum Institute of India’s (SII) first indigenously designed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer today.
Prakash Kumar Singh filed a market authorization application for the qHPV vaccination with the DCGI on June 8. (Director of government and regulatory affairs). Singh’s application to the DCGI describes the vaccine’s antibody response against HPV types in all doses and age groups.
The vaccine is said to be scheduled to hit the market by the end of 2022. The qHPV vaccine will be India’s first indigenously curated cervical cancer vaccine.
After completing the phase 2/3 clinical trial with the help of the Department of Biotechnology, the Pune-based Serum Institute of India submitted for market permission to assure its early availability in the country.
